1498 related articles for article (PubMed ID: 17705185)
1. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
Nebbia G; Garcia-Diaz A; Ayliffe U; Smith C; Dervisevic S; Johnson M; Gilson R; Tedder R; Geretti AM
J Med Virol; 2007 Oct; 79(10):1464-71. PubMed ID: 17705185
[TBL] [Abstract][Full Text] [Related]
2. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI
J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397
[TBL] [Abstract][Full Text] [Related]
3. Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India.
Gupta S; Singh S
BMC Infect Dis; 2010 Mar; 10():53. PubMed ID: 20205948
[TBL] [Abstract][Full Text] [Related]
4. Occult hepatitis B virus infection in HIV-infected patients with isolated hepatitis B core antibody.
Azadmanesh K; Mohraz M; Aghakhani A; Edalat R; Jam S; Eslamifar A; Banifazl M; Moradmand-Badie B; Ramezani A
Intervirology; 2008; 51(4):270-4. PubMed ID: 18841029
[TBL] [Abstract][Full Text] [Related]
5. [Investigation of occult hepatitis B in HIV infected patients].
Altınbaş A; Ergünay K; Calık Başaran N; Alp A; Turgut D; Hasçelik G; Uzun Ö; Unal S
Mikrobiyol Bul; 2011 Apr; 45(2):353-8. PubMed ID: 21644079
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission.
Rai RR; Mathur A; Mathur D; Udawat HP; Nepalia S; Nijhawan S; Mathur A
Trop Gastroenterol; 2007; 28(1):19-23. PubMed ID: 17896605
[TBL] [Abstract][Full Text] [Related]
7. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy.
Sheng WH; Kao JH; Chen PJ; Huang LM; Chang SY; Sun HY; Hung CC; Chen MY; Chang SC
Clin Infect Dis; 2007 Nov; 45(9):1221-9. PubMed ID: 17918088
[TBL] [Abstract][Full Text] [Related]
8. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
[TBL] [Abstract][Full Text] [Related]
9. Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?
Rodríguez-Torres M; Gonzalez-Garcia J; Bräu N; Solá R; Moreno S; Rockstroh J; Smaill F; Mendes-Correa MC; DePamphilis J; Torriani FJ;
J Med Virol; 2007 Jun; 79(6):694-700. PubMed ID: 17457912
[TBL] [Abstract][Full Text] [Related]
10. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
[TBL] [Abstract][Full Text] [Related]
11. Occult hepatitis B virus infection.
Allain JP
Transfus Clin Biol; 2004 Feb; 11(1):18-25. PubMed ID: 14980545
[TBL] [Abstract][Full Text] [Related]
12. Anti-hepatits B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice.
Bhatti FA; Ullah Z; Salamat N; Ayub M; Ghani E
Transfusion; 2007 Jan; 47(1):74-9. PubMed ID: 17207233
[TBL] [Abstract][Full Text] [Related]
13. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
14. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy.
Filippini P; Coppola N; Pisapia R; Scolastico C; Marrocco C; Zaccariello A; Nacca C; Sagnelli C; De Stefano G; Ferraro T; De Stefano C; Sagnelli E
AIDS; 2006 Jun; 20(9):1253-60. PubMed ID: 16816553
[TBL] [Abstract][Full Text] [Related]
15. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa.
Mphahlele MJ; Lukhwareni A; Burnett RJ; Moropeng LM; Ngobeni JM
J Clin Virol; 2006 Jan; 35(1):14-20. PubMed ID: 15916918
[TBL] [Abstract][Full Text] [Related]
16. High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.
Laurent C; Bourgeois A; Mpoudi-Ngolé E; Kouanfack C; Ciaffi L; Nkoué N; Mougnutou R; Calmy A; Koulla-Shiro S; Ducos J; Delaporte E
HIV Med; 2010 Jan; 11(1):85-9. PubMed ID: 19659944
[TBL] [Abstract][Full Text] [Related]
17. Occult hepatitis B virus infection in HIV-infected Lebanese patients with isolated antibodies to hepatitis B core antigen.
Ramia S; Mokhbat J; Ramlawi F; El-Zaatari M
Int J STD AIDS; 2008 Mar; 19(3):197-9. PubMed ID: 18397562
[TBL] [Abstract][Full Text] [Related]
18. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital.
Lukhwareni A; Burnett RJ; Selabe SG; Mzileni MO; Mphahlele MJ
J Med Virol; 2009 Mar; 81(3):406-12. PubMed ID: 19152393
[TBL] [Abstract][Full Text] [Related]
19. [Investigation of hemodialysis patients in terms of the presence of occult hepatitis B].
Altindiş M; Uslan I; Cetinkaya Z; Yüksel S; Ciftçi IH; Demirtürk N; Ozdemir M; Arslan F; Aktepe OC
Mikrobiyol Bul; 2007 Apr; 41(2):227-33. PubMed ID: 17682709
[TBL] [Abstract][Full Text] [Related]
20. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
